Experimental Drug Burns Fat in Obese Mice Without Appetite Suppression

For decades, the pharmaceutical approach to obesity has followed a simple logic: make people eat less. Appetite suppressants dominate the market. But researchers at UC Berkeley have been testing a different premise—what if the body could simply burn more of what it takes in?

That question led them to an old compound called TOFA, or 5-tetradecyloxy-2-furoic acid, first synthesized in the 1970s and sitting in laboratory supply catalogs ever since. Nobody had thought to look at it as a weight-loss agent. When the Berkeley team fed it to obese mice twice daily for four weeks, something unexpected happened: the animals lost an average of 18 percent of their body weight without eating any less food.

The mice did not move around more. Their body temperature did not spike. They were not absorbing fewer calories. Yet their whole-body energy expenditure climbed by as much as 18 percent—meaning their cells were burning fuel at a higher rate. Most of the weight shed came from fat. Muscle and lean tissue remained largely intact, a distinction that matters enormously in weight loss, where the body often cannibalizes its own structural tissue alongside fat stores.

Anders Näär, the metabolic biologist who led the work, described the mechanism in surprisingly simple terms: TOFA appears to slow the production of new fat while simultaneously helping cells take up and burn existing fat for energy. Yet when the researchers tried to replicate these effects by combining two separate drugs—one to inhibit fat production, another to boost fat burning—the results fell short of what TOFA alone achieved. Something about having both activities in a single molecule mattered in ways the team does not yet fully understand.

The benefits extended beyond the scale. TOFA lowered blood sugar and insulin levels in the treated mice, improved their glucose response, and reduced circulating fat and liver fat. In separate experiments, it also reversed markers of fatty liver disease—the fat accumulation, inflammation, and scarring that often accompany obesity. The compound had stumbled into a broader metabolic improvement, not merely cosmetic weight loss.

The real intrigue emerged when Näär's team combined low-dose TOFA with existing appetite-suppressing drugs like semaglutide and tirzepatide. These GLP-1-based medications work by making people eat less. TOFA works by making the body burn more. Together, they produced greater weight loss and metabolic gains than either approach alone. The two mechanisms operate on opposite sides of the energy equation, complementing rather than duplicating each other. When TOFA-treated mice stopped receiving the drug, they maintained their weight longer than mice that had been given semaglutide alone, which rapidly regained weight as their appetite returned.

But the path from mouse to human is long and uncertain. TOFA has never been tested in a person. The lowest effective dose remains unknown. The study used only male mice, leaving open the question of whether females would respond similarly. The researchers acknowledge that TOFA requires toxicology and safety testing in rats and larger animals before any human trials can begin. Näär and two co-authors have financial stakes in ReRx Therapeutics, the company developing TOFA as a potential treatment, a detail worth noting as the work moves forward.

For now, TOFA exists in that liminal space where promising science meets the hard reality of drug development. What the Berkeley findings do offer is a proof of concept: obesity might be tackled not only by suppressing appetite, but by fundamentally altering how the body processes energy. That shift in thinking could reshape how researchers approach metabolic disease in the years ahead.